KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Divestments (2025)

Recursion Pharmaceuticals (RXRX) has disclosed Divestments for 1 consecutive years, with -$4.4 million as the latest value for Q1 2025.

  • For the quarter ending Q1 2025, Divestments changed N/A year-over-year to -$4.4 million, compared with a TTM value of -$4.4 million through Dec 2025, changed N/A, and an annual FY2025 reading of -$4.4 million, changed N/A over the prior year.
  • Divestments was -$4.4 million for Q1 2025 at Recursion Pharmaceuticals.
  • Across five years, Divestments topped out at -$4.4 million in Q1 2025 and bottomed at -$4.4 million in Q1 2025.